News >

Liquid Biopsy Demonstrates Prognostic Potential in Metastatic TNBC

Jason Harris
Published: Tuesday, Feb 20, 2018

Heather Parsons, MD
Heather Parsons, MD
Low-coverage genome-wide sequencing of cell-free DNA (cfDNA) from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer (mTNBC), according to results from a retrospective study published in the Journal of Clinical Oncology.

“This is a very challenging disease. Our team's findings—and others enabled by liquid biopsy—could improve how we track disease and treat our patients in the clinic," says Heather Parsons, MD, co-first author of the study and breast medical oncologist/researcher at Dana-Farber Cancer Institute and Harvard Medical School, said in a statement.
Stover DG, Parsons HA, Ha G, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018; 36:543-553. doi: 10.1200/JCO.2017.76.0033.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x